⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.
Cariprazine
کاریپرازین
🧠 Nervous SystemAtypical antipsychotic
🤰 Pregnancy:Dangerous / avoid🤱 Breastfeeding:Use with caution👶 Children:Dangerous / avoid👴 Older adults:Dangerous / avoid 🇮🇷 Not found in Iran list⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA204370ATC N05AX15
Market / country: 🇺🇸 USA
Vraylar (US)
🧮 Dose calculator
Schizophrenia · Regimen source: FDA Vraylar · 2.2
- • May increase to 3 mg on day 2. Long half-life: dose changes take weeks to show. FDA Vraylar · 2.2FDA Vraylar · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ History of hypersensitivity to cariprazine. FDA Vraylar · 4
Warnings
- • Boxed warning: increased mortality in elderly patients with dementia-related psychosis; suicidal thoughts in children and young adults. FDA Vraylar · Boxed Warning
Formulations
- 1.5 mg capsule — capsule 🇺🇸 USA FDA Vraylar · 3
- 3 mg capsule — capsule 🇺🇸 USA FDA Vraylar · 3
- 4.5 mg capsule — capsule 🇺🇸 USA FDA Vraylar · 3
- 6 mg capsule — capsule 🇺🇸 USA FDA Vraylar · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Vraylar · 8.1
“Based on animal data, VRAYLAR may cause fetal harm.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Vraylar · 8.2
“Risk Summary Lactation studies have not been conducted to assess the presence of cariprazine in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Vraylar · Boxed Warning
“Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.”
- 👴 Older adultsDangerous / avoid
Label: serious warning or avoid in older adults. FDA Vraylar · Boxed Warning
“Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA204370
- DailyMed (FDA label)FDA Vraylar
- MedlinePlus (NIH)Cariprazine
- WHO ATC/DDDN05AX15
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Vraylar · 3FDA Vraylar · 2.2FDA Vraylar · 2.1FDA Vraylar · 2.3FDA Vraylar · 2.4FDA Vraylar · 2.5FDA Vraylar · 4FDA Vraylar · Boxed WarningFDA Vraylar · SPL approval / marketing categoryFDA Vraylar · 8.1FDA Vraylar · 8.2
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified